Aspire-Lakewood (ASBP)
Market Price (10/12/2026): $8.41 | Market Cap: $8.7 MilSector: Consumer Discretionary | Industry: Automotive Parts & Equipment
Aspire-Lakewood (ASBP)
Market Price (10/12/2026): $8.41Market Cap: $8.7 MilSector: Consumer DiscretionaryIndustry: Automotive Parts & Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -141% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -136%, 3Y Excs Rtn is -183% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7260% Expensive valuation multiplesP/SPrice/Sales ratio is 88x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 161% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7358%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7358% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 264% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -134% High stock price volatilityVol 12M is 173% Key risksASBP key risks include [1] significant financial distress raising substantial doubt about its ability to continue as a going concern and [2] a potential delisting from Nasdaq for non-compliance. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -141% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -136%, 3Y Excs Rtn is -183% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7260% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 88x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 161% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7358%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7358% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 264% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -134% |
| High stock price volatilityVol 12M is 173% |
| Key risksASBP key risks include [1] significant financial distress raising substantial doubt about its ability to continue as a going concern and [2] a potential delisting from Nasdaq for non-compliance. |
Qualitative Assessment
AI Analysis | Feedback
Aspire-Lakewood (ASBP) stock has gained about 55% since 6/30/2026 because of the following key factors:
1. Strategic Acquisition of Dura Driver Control Systems (DCS).
Aspire-Lakewood Holdings, Inc. completed the acquisition of Dura Driver Control Systems (DCS) for $30 million on August 10, 2026, within fiscal Q3 2026. This acquisition significantly enhanced Aspire-Lakewood's financial profile, as DCS generated approximately $209.5 million in revenue and $22.3 million in Adjusted EBITDA in fiscal year 2025. Furthermore, for the six months ended June 30, 2026 (fiscal Q1 and Q2 2026), DCS contributed approximately $103.9 million in revenue and $10.5 million in Adjusted EBITDA.
2. Expanded Share Repurchase Program.
On September 9, 2026, within fiscal Q3 2026, Aspire-Lakewood's Board of Directors authorized an expanded $10 million common stock repurchase program. This program, reflecting management's confidence in the company's financial strength and growth opportunities, is particularly impactful given that the company had approximately 1.5 million common shares outstanding as of September 8, 2026.
Show more
Aspire-Lakewood (ASBP) stock has gained about 55% since 6/30/2026 because of the following key factors:
1. Strategic Acquisition of Dura Driver Control Systems (DCS).
Aspire-Lakewood Holdings, Inc. completed the acquisition of Dura Driver Control Systems (DCS) for $30 million on August 10, 2026, within fiscal Q3 2026. This acquisition significantly enhanced Aspire-Lakewood's financial profile, as DCS generated approximately $209.5 million in revenue and $22.3 million in Adjusted EBITDA in fiscal year 2025. Furthermore, for the six months ended June 30, 2026 (fiscal Q1 and Q2 2026), DCS contributed approximately $103.9 million in revenue and $10.5 million in Adjusted EBITDA.
2. Expanded Share Repurchase Program.
On September 9, 2026, within fiscal Q3 2026, Aspire-Lakewood's Board of Directors authorized an expanded $10 million common stock repurchase program. This program, reflecting management's confidence in the company's financial strength and growth opportunities, is particularly impactful given that the company had approximately 1.5 million common shares outstanding as of September 8, 2026.
3. Corporate Rebranding and Strategic Expansion.
In September 2026, during fiscal Q3 2026, the company officially changed its name from Aspire Biopharma Holdings, Inc. to Aspire-Lakewood Holdings, Inc. This rebranding signifies a strategic pivot towards a holding company structure, integrating new business segments like the automotive industry through the DCS acquisition, alongside its existing biopharma ventures. The company's fiscal year runs from January to December.
Show less
Stock Movement Drivers
Fundamental Drivers
The 55.4% change in ASBP stock from 6/30/2026 to 10/11/2026 was primarily driven by a 264.3% change in the company's P/S Multiple.| (LTM values as of) | 6302026 | 10112026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.34 | 8.30 | 55.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 182.6% |
| P/S Multiple | 24.2 | 88.2 | 264.3% |
| Shares Outstanding (Mil) | 0 | 1 | -84.9% |
| Cumulative Contribution | 55.4% |
Market Drivers
6/30/2026 to 10/11/2026| Return | Correlation | |
|---|---|---|
| ASBP | 55.4% | |
| Market (SPY) | 4.3% | 41.9% |
| Sector (XLY) | -3.8% | 29.7% |
Fundamental Drivers
The -73.1% change in ASBP stock from 3/31/2026 to 10/11/2026 was primarily driven by a -88.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312026 | 10112026 | Change |
|---|---|---|---|
| Stock Price ($) | 30.90 | 8.30 | -73.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 1474.6% |
| P/S Multiple | 586.8 | 88.2 | -85.0% |
| Shares Outstanding (Mil) | 0 | 1 | -88.7% |
| Cumulative Contribution | -73.1% |
Market Drivers
3/31/2026 to 10/11/2026| Return | Correlation | |
|---|---|---|
| ASBP | -73.1% | |
| Market (SPY) | 20.0% | 24.4% |
| Sector (XLY) | 3.8% | 13.2% |
Fundamental Drivers
The -96.6% change in ASBP stock from 9/30/2025 to 10/11/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 10112026 | Change |
|---|---|---|---|
| Stock Price ($) | 247.20 | 8.30 | -96.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 88.2 | |
| Shares Outstanding (Mil) | 0 | 1 | -96.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 10/11/2026| Return | Correlation | |
|---|---|---|
| ASBP | -96.6% | |
| Market (SPY) | 17.8% | 17.7% |
| Sector (XLY) | -5.3% | 11.4% |
Fundamental Drivers
nullnull
Market Drivers
9/30/2023 to 10/11/2026| Return | Correlation | |
|---|---|---|
| ASBP | -99.9% | |
| Market (SPY) | 88.4% | 12.4% |
| Sector (XLY) | 43.4% | 9.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ASBP Return | - | 3% | 6% | 6% | -99% | -95% | -100% |
| Peers Return | -3% | -55% | 12% | -22% | 23% | -19% | -62% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 107% |
Monthly Win Rates [3] | |||||||
| ASBP Win Rate | - | 78% | 75% | 67% | 50% | 20% | |
| Peers Win Rate | 48% | 30% | 40% | 35% | 55% | 42% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ASBP Max Drawdown | - | - | -12% | -12% | -99% | -97% | |
| Peers Max Drawdown | -41% | -64% | -46% | -55% | -44% | -42% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AQST, TNXP, MGA, LEA, APTV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/9/2026 (YTD)
About Aspire-Lakewood (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP) is an early-stage biopharmaceutical company dedicated to developing and marketing innovative drug delivery mechanisms. Its primary focus is on creating disruptive technologies for administering existing "do no harm" drugs, particularly through sublingual (under the tongue) formulations. The company aims to improve drug efficacy, speed of action, convenience, and patient compliance for a wide range of medications.
Currently, Aspire Biopharma's flagship offering is a Sublingual Aspirin Product, engineered to rapidly address cardiology emergencies and manage pain effectively. Beyond aspirin, the company boasts an extensive pipeline of sublingually administered product formulations. These include a melatonin sleep-aid, essential vitamins (D, E, K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is developing formulations for anti-nausea, anti-psychotic, erectile dysfunction (ED), and seizure medications, among several other drug classes.
Serving the United States market, Aspire Biopharma targets a diverse patient base that stands to benefit from enhanced drug delivery across numerous therapeutic areas. By focusing on improving the administration of well-known medications, the company seeks to carve out a niche in providing more convenient and potentially more effective treatment options for patients in areas such as cardiovascular health, pain management, sleep disorders, hormone therapy, and neurological conditions.
AI Analysis | Feedback
1. Viatris for sublingual drug delivery
2. Moderna for drug delivery platforms
3. Dyson for drug delivery mechanisms
AI Analysis | Feedback
- Sublingual Aspirin Product: This product addresses cardiology emergencies and pain management through a sublingual delivery mechanism.
- Sublingual Melatonin Sleep-Aid: A formulation under development aimed at providing sleep assistance through sublingual administration.
- Sublingual Vitamins (D, E, K): Formulations currently under development for sublingual delivery of essential vitamins.
- Sublingual Testosterone: A formulation under development for hormone replacement therapy via sublingual means.
- Sublingual Semaglutide: A formulation under development for sublingual administration of semaglutide, typically used for diabetes or weight management.
- Sublingual Anti-Nausea Products: Formulations under development designed to combat nausea through sublingual delivery.
- Sublingual Anti-Psychotic Products: Formulations under development for the sublingual treatment of psychotic disorders.
- Sublingual ED Drugs: Formulations under development for sublingual administration of erectile dysfunction medications.
- Sublingual Seizure Medication: Formulations under development for managing seizures via a sublingual delivery mechanism.
AI Analysis | Feedback
Major Customers of Aspire-Lakewood (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP) is an early-stage biopharmaceutical company focused on developing and marketing disruptive technology for drug delivery mechanisms and formulations. Based on the provided description, the company operates primarily within a business-to-business (B2B) model, developing products and technologies that would typically be sold or licensed to other entities within the pharmaceutical and healthcare sectors.
The provided background information does not identify any specific major customer companies by name.
However, given ASBP's business nature as an early-stage biopharmaceutical developer, its major customers would typically fall into the following categories:
- Pharmaceutical Companies: These would be the primary customers for licensing or acquiring ASBP's proprietary drug formulations and delivery technologies. Such companies would then handle further development, regulatory approvals, manufacturing, and widespread commercialization of the products.
- Drug Distributors and Wholesalers: If ASBP progresses to manufacturing and directly selling its own finished pharmaceutical products, these companies would serve as essential intermediaries, purchasing the products for distribution to pharmacies, hospitals, clinics, and other healthcare providers.
AI Analysis | Feedback
AI Analysis | Feedback
Kraig Higginson, Chief Executive Officer, President and Executive Chairman of the Board
Kraig Higginson currently serves as the Interim Chief Executive Officer, President, and Executive Chairman of the Board for Aspire-Lakewood Holdings, Inc.. He previously served as CEO of Aspire Biopharma for four years. Higginson has also held executive roles at other companies, including Executive Chairman at Raser Technologies, Inc., and President & Chief Executive Officer at American Telemedia Network, Inc. He also served on the board of VIA Motors, Inc..
Ernest J. Scheidemann Jr., Chief Financial Officer
Ernest J. Scheidemann Jr. is the Chief Financial Officer of Aspire-Lakewood Holdings, Inc.. He brings over 25 years of C-level experience, having served as CFO for numerous companies ranging from entrepreneurial startups to Fortune 500 entities. Notably, he founded National Home Corporation, a nationwide production homebuilder, where he also served as CFO. His experience includes being CFO for ASG Technologies, Inc., which was acquired by Rocket Software, and WCI Communities, Inc., which was acquired by Lennar. Scheidemann has extensive experience with private equity-backed companies.
Stephen E. Quesenberry, General Counsel & Corporate Secretary
Stephen E. Quesenberry serves as the General Counsel & Corporate Secretary of Aspire-Lakewood Holdings, Inc.. He is a legal professional with a practice focused on civil litigation, particularly in the areas of real estate, construction, and securities fraud. He has experience conducting jury and bench trials across the United States and in Utah. His clientele has included Kraig Higginson. He is a member of Durham Jones & Pinegar's Litigation and Real Estate Sections.
AI Analysis | Feedback
The key risks for Aspire-Lakewood (ASBP) largely stem from its status as an early-stage biopharmaceutical company developing novel drug delivery technologies. These risks include significant financial distress, the threat of Nasdaq delisting, and the inherent challenges associated with regulatory approval and clinical trial success in the biopharmaceutical industry.
-
Financial Distress and Liquidity Concerns: Aspire-Lakewood is currently facing substantial financial uncertainty, characterized by a surge in long-term debt and rapidly depleting cash reserves. Recent financial reports indicate deep distress, with stubbornly high operating costs and little improvement in revenue streams. The company's gross margin, despite appearing positive, is overshadowed by a negative return on assets of -1,110.97%. This poor financial strength and profitability suggest a high likelihood of further financial distress, raising significant concerns about its ability to sustain operations and fund its ongoing development efforts.
-
Nasdaq Delisting and Market Capitalization Issues: The company has received multiple notices from Nasdaq regarding non-compliance with listing standards, specifically concerning its minimum market value of listed securities (MVLS) and minimum bid price. Aspire-Lakewood's market capitalization is less than US$10 million, a factor considered a major risk for companies that have not yet commercialized products or have a limited market reach. While the company has appealed the delisting determination and is pursuing actions like a reverse stock split to regain compliance, the ongoing threat of delisting significantly impacts its public visibility and access to capital markets.
-
Regulatory, Clinical, and Technology Risk: As a biopharmaceutical company, Aspire-Lakewood's success is critically dependent on its pharmaceutical candidates successfully completing rigorous FDA review and extensive clinical testing. The biopharmaceutical industry is known for its lengthy development pipelines, with FDA approval being a challenging and often prolonged process, sometimes taking an average of 14 years for a new drug. The company's focus on "disruptive technology for delivery mechanisms" also introduces unique regulatory hurdles and the need to prove the safety and efficacy of these novel methods. Failures or delays at any stage of clinical trials or in obtaining regulatory approvals would severely hinder the commercialization of its products.
AI Analysis | Feedback
AI Analysis | Feedback
Aspire-Lakewood (symbol: ASBP) is an early-stage biopharmaceutical company focused on developing and marketing disruptive sublingual drug delivery mechanisms. Based on available information, the addressable markets for its main products and services are as follows:
- Sublingual Aspirin Product (for cardiology emergencies and pain management): The market opportunity for sublingual aspirin, specifically addressing the combined opioid and non-opioid markets, is estimated at approximately US$80 billion currently and is expected to grow to US$100 billion over the next five years. This market size is global.
- Sublingually administered melatonin sleep-aid product: This product falls under the broader VMS (Vitamins, Minerals, and Supplements) Sublingual Products Market. The global VMS Sublingual Products Market was valued at USD 12,932.0 million (USD 12.93 billion) in 2024 and is projected to reach USD 24,654.7 million (USD 24.65 billion) by 2032. For North America, this market was USD 4,836.6 million (USD 4.84 billion) in 2024 and is projected to reach USD 8,185.4 million (USD 8.19 billion) by 2032.
- Vitamins D, E, and K (sublingual formulations): These products are also part of the VMS Sublingual Products Market. The global VMS Sublingual Products Market was valued at USD 12,932.0 million (USD 12.93 billion) in 2024 and is projected to reach USD 24,654.7 million (USD 24.65 billion) by 2032. In North America, this market was USD 4,836.6 million (USD 4.84 billion) in 2024 and is projected to reach USD 8,185.4 million (USD 8.19 billion) by 2032.
- Semaglutide (sublingual formulation): Aspire's semaglutide formulation targets the oral semaglutide market. The global Rybelsus (oral semaglutide) segment generated a revenue of USD 4,429.6 million (USD 4.43 billion) in 2025 and is expected to reach USD 12,662.5 million (USD 12.66 billion) by 2035. North America was the largest revenue-generating market for oral semaglutide in 2025.
- For sublingual testosterone, anti-nausea products, anti-psychotic products, ED drugs, and seizure medication (sublingual formulations), specific addressable market sizes for the sublingual delivery mechanism were not identified.
AI Analysis | Feedback
- Integration and Growth from the Dura Driver Control Systems (DCS) Acquisition: Aspire-Lakewood Holdings, Inc. completed the acquisition of DURA Automotive Systems, LLC (DCS), a tier-one global automotive supplier, on August 10, 2026. DCS reported approximately $209.5 million in revenue for 2025 and $103.9 million for the unaudited six months ended June 30, 2026. This acquisition is a significant move to diversify the company and is expected to contribute substantial revenue and cash flow, pivoting Aspire into a higher-revenue enterprise.
- Commercialization of the Sublingual Aspirin Product: The company's lead product candidate, a sublingual high-dose aspirin formulation, is targeted for New Drug Application (NDA) submission to the FDA in the second half of 2025. This fast-acting aspirin is designed for cardiology emergencies and pain management and has demonstrated rapid blood clot inhibition in clinical trials, acting faster than traditional chewed aspirin tablets.
- Development and Launch of New Sublingual Drug Formulations: Aspire-Lakewood is actively advancing a pipeline of additional sublingually administered products. Key candidates for which formulation finalization and clinical testing are scheduled for the first half of 2026 include a sublingual erectile dysfunction (ED) medication and a sublingual semaglutide formulation, aimed at diabetes and weight management. The company is also exploring formulations for anti-nausea, anti-psychotic, and seizure medications, as well as melatonin, vitamins D, E, and K, and testosterone.
- Expansion of the BUZZ BOMB™ Caffeine Product Line: Aspire-Lakewood has launched its sublingual caffeine product, BUZZ BOMB™, through a direct-to-consumer website and is pursuing broader retail expansion. The company is actively promoting this supplement at fitness expos and has entered into agreements to drive national retail distribution. This consumer segment is identified as a high-growth area for the company.
AI Analysis | Feedback
Share Repurchases
- Aspire Biopharma (ASBP) announced a board-authorized stock repurchase program for up to $5 million of its common stock on April 27, 2026.
- On September 9, 2026, Aspire-Lakewood Holdings authorized a $10 million common stock repurchase program.
Share Issuance
- Aspire secured $21 million in private placement financing through preferred stock offerings in February and April 2026.
- Following a business combination on February 20, 2025, the company had 46,007,513 shares of New Aspire Common Stock issued and outstanding.
- Aspire Biopharma effected a one-for-thirty reverse stock split on May 11, 2026.
Inbound Investments
- The company received $21 million in private placement financing from select institutional and accredited investors in February and April 2026, through preferred stock offerings.
- In February 2026, the initial closing of the private placement offering generated gross proceeds of $11.0 million, with a portion used to support business operations, fund strategic initiatives, and repay legacy indebtedness.
- On February 20, 2025, the company issued Debentures with an aggregate principal amount of $3,750,000 for a purchase price of $3,000,000, reflecting a 20% original issue discount.
Outbound Investments
- Aspire entered a binding Letter of Intent on April 15, 2026, to acquire Dura Driver Control Systems (DCS) for approximately $30 million in cash.
- Aspire Biopharma signed a definitive share purchase agreement to acquire Dura Automotive Systems, LLC for $30 million on June 12, 2026.
- The acquisition of DURA Automotive Systems, LLC for $30 million was completed on August 10, 2026, and was partly financed by a $22.5 million senior secured revolving credit facility.
Capital Expenditures
- Aspire-Lakewood Holdings invested $233K in research and development in Q2 2026.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 25.85 |
| Mkt Cap | 3.3 |
| Rev LTM | 9,390 |
| Op Inc LTM | 432 |
| FCF LTM | 338 |
| FCF 3Y Avg | 328 |
| CFO LTM | 672 |
| CFO 3Y Avg | 622 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.3% |
| Rev Chg 3Y Avg | 2.9% |
| Rev Chg Q | 3.3% |
| QoQ Delta Rev Chg LTM | 4.2% |
| Op Inc Chg LTM | 0.5% |
| Op Inc Chg 3Y Avg | 1.1% |
| Op Mgn LTM | -46.9% |
| Op Mgn 3Y Avg | 3.7% |
| QoQ Delta Op Mgn LTM | 6.9% |
| CFO/Rev LTM | -38.8% |
| CFO/Rev 3Y Avg | 5.0% |
| FCF/Rev LTM | -40.7% |
| FCF/Rev 3Y Avg | 2.6% |
Price Behavior
| Market Price | $8.30 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/11/2022 | |
| Distance from 52W High | -98.4% | |
| 50 Days | 200 Days | |
| DMA Price | $8.24 | $26.22 |
| DMA Trend | up | down |
| Distance from DMA | 0.8% | -68.4% |
| 3M | 1YR | |
| Volatility | 93.4% | 173.3% |
| Downside Capture | 146.98 | 391.24 |
| Upside Capture | 291.52 | -130.09 |
| Correlation (S&P 500) | 45.7% | 19.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.87 | 1.40 | 3.60 | 3.17 | 2.62 | 1.40 |
| Up Beta | 3.35 | 1.27 | 4.54 | 4.07 | 1.26 | 1.05 |
| Down Beta | -5.29 | -0.60 | 9.09 | 5.87 | 5.44 | 2.80 |
| Up Capture | 124% | 251% | 375% | -13% | -38% | -5% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 11 | 21 | 34 | 60 | 111 | 256 |
| Down Capture | 134% | 30% | 73% | 269% | 187% | 113% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 11 | 21 | 30 | 66 | 140 | 291 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullEarnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Industry Resources
| Consumer Discretionary Resources |
| Retail Dive |
| Business of Fashion (BoF) |
| WWD (Women's Wear Daily) |
| National Retail Federation (NRF) |
| McKinsey & Company - Consumer |
| Mintel Consumer Trends |
| Automotive Parts & Equipment Resources |
| AftermarketNews |
| Tire Review |
| Motor Age |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.